These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12828227)

  • 1. The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI.
    Messerli AW; Aronow HD; Sprecher DL
    Cleve Clin J Med; 2003 Jun; 70(6):561-6. PubMed ID: 12828227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA; Chaplin S
    Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
    Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P;
    Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.
    Scuffham PA; Chaplin S
    Clin Ther; 2005 Sep; 27(9):1467-77. PubMed ID: 16291420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.
    Serruys PW; de Feyter P; Macaya C; Kokott N; Puel J; Vrolix M; Branzi A; Bertolami MC; Jackson G; Strauss B; Meier B;
    JAMA; 2002 Jun; 287(24):3215-22. PubMed ID: 12076217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
    Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention.
    Scuffham PA; Kósa J
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):309-17. PubMed ID: 16779529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
    Lemos PA; Serruys PW; de Feyter P; Mercado NF; Goedhart D; Saia F; Arampatzis CA; Soares PR; Ciccone M; Arquati M; Cortellaro M; Rutsch W; Legrand V
    Am J Cardiol; 2005 Feb; 95(4):445-51. PubMed ID: 15695126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.
    Holdaas H; Fellström B; Holme I; Nyberg G; Fauchald P; Jardine A; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Weinreich T; Olsson AG; Pedersen TR; Benghozi R; Hartmann A;
    J Cardiovasc Risk; 2001 Apr; 8(2):63-71. PubMed ID: 11324372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS).
    Lee CH; de Feyter P; Serruys PW; Saia F; Lemos PA; Goedhart D; Soares PR; Umans VA; Ciccone M; Cortellaro M
    Heart; 2004 Oct; 90(10):1156-61. PubMed ID: 15367512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
    Herd JA
    Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
    Lemos PA; de Feyter PJ; Serruys PW; Saia F; Arampatzis CA; Disco C; Mercado N; Mainar V; Morís C; van den Bos AA; Berghoefer G
    Int J Cardiol; 2005 Feb; 98(3):479-86. PubMed ID: 15708183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS.
    Lesaffre E; Kocmanová D; Lemos PA; Disco CM; Serruys PW
    Clin Ther; 2003 Sep; 25(9):2431-47. PubMed ID: 14604742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing cardiac events and restenosis after percutaneous coronary intervention.
    Sopko G
    JAMA; 2002 Jun; 287(24):3259-61. PubMed ID: 12076224
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluvastatin: a review of its use in lipid disorders.
    Langtry HD; Markham A
    Drugs; 1999 Apr; 57(4):583-606. PubMed ID: 10235694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
    Herd JA; West MS; Ballantyne C; Farmer J; Gotto AM
    Am J Cardiol; 1994 May; 73(14):42D-49D. PubMed ID: 8198024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial.
    Lloyd GW; Jackson G; Foley DP; Boersma E; Shepherd J; Serruys PW
    Atherosclerosis; 2001 Oct; 158(2):445-54. PubMed ID: 11583725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of the month. The LIPS study: fluvastatin for prevention of cardiac events following percutaneous coronary angioplasty].
    Scheen AJ
    Rev Med Liege; 2002 Jul; 57(7):479-82. PubMed ID: 12233226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.